An improved animal model to assess bone marrow and systemic toxicity of CXCR4-targeting radiopharmaceuticals (EANM 2026) - Sep 29, 2026 - Abstract #OP-861; Pres time: Oct 21, 2026; 09:45 AM - 11:15 AM; Location: Hall E1; "Several commercial CXCR4 inhibitors (LY2510924, Mavorixafor, and Plerixafor) were observed to block EL4::hCXCR4 uptake of [18F]BL40 <1%, confirming the specificity for hCXCR4. The results highlight the usefulness of humanized mouse models when significant interspecies differences in radiotracer binding exist. In the context of CXCR4 radiopharmaceutical therapy, such models may allow better assessment of strategies to manage on-target, off-tumor toxicity."
Preclinical • Hematological Malignancies • Lymphoma • CXCR4
|
|
E. Friesen 1, 2; I. Astiazarán-Rascón 1, 2; F. Cookson 2; P. Ng 2; H. Merkens 2; J. Zeisler 2; J. Pan 3; I. Alberts 3; J. Lau 1, 2; K. Lin 1, 2; F. Bénard 1, 2, 3
|